Chinese expert consensus on anti-HER2 therapy for gastric cancer(2024 edition)
10.12354/j.issn.1000-8179.2024.20241401
- VernacularTitle:胃癌抗HER2治疗中国专家共识(2024年版)
- Author:
Liang HAN
;
Li ZIYU
;
Zhang XIAOTIAN
;
Zhang YANQIAO
- Collective Name:Gastric Cancer Committee of China Anti-Cancer Association
- Publication Type:Journal Article
- Keywords:
gastric cancer(GC);
human epidermal growth factor receptor 2(HER2);
anti-HER2 therapy;
expert consensus
- From:
Chinese Journal of Clinical Oncology
2024;51(23):1189-1205
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer(GC)is one of the most common malignant tumors of the digestive system.Human epidermal growth factor re-ceptor 2(HER2)is an important therapeutic target in GC.In recent years,anti-HER2 agents have made significant breakthroughs in GC treat-ment,providing more options for patients.To better guide the rational,effective,and safe application of anti-HER2 therapy in clinical prac-tice,the Gastric Cancer Committee of China Anti-Cancer Association assembled domestic experts in the field of GC.After multiple rounds of discussions,they systematically reviewed domestic and international evidence-based data and integrated it with clinical practices in China.As a result,they formulated the"Chinese expert consensus on anti-HER2 therapy for gastric cancer(2024 edition)"to address the use of anti-HER2 therapy in advanced and perioperative settings,conversion therapy,and key considerations during treatment.This consensus aimed to further standardize and guide the clinical practice of anti-HER2 therapy for GC.
